Actively Recruiting
Prospective Clinical Study of 18F-Pentixafor PET Imaging in Hematologic Malignancies
Led by First Affiliated Hospital of Zhejiang University · Updated on 2025-08-14
100
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the use of 18F-Pentixafor PET imaging to improve the diagnosis, staging, and response evaluation of hematological malignancies such as multiple myeloma, leukemia, and lymphoma. This imaging method targets the CXCR-4 receptor, which is overexpressed in these tumors and is linked to tumor growth and poor prognosis. The study aims to assess how well 18F-Pentixafor PET performs compared to current imaging methods like 18F-FDG PET. Participants will receive a single intravenous injection of 18F-Pentixafor at a dose of 55 MBq/kg. After 60 minutes, they will undergo either a PET/CT or PET/MR scan. This process allows for detailed imaging without special preparation. The study includes patients with suspected or confirmed hematological malignancies and involves only one imaging session per participant. During the study, researchers will monitor diagnostic accuracy and compare 18F-Pentixafor PET's performance with traditional 18F-FDG PET imaging. They will also assess disease activity using the Deauville Score over a period of up to 3-4 years. Participants will be involved in imaging procedures and may undergo biopsies if needed for diagnosis. The study will continue until December 2029, with an average follow-up of about 1.5 years for primary outcome assessment.
CONDITIONS
Brief Title
18F-Pentixafor PET in Hematologic Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years, any gender, with ability to consent and comply
- Patients with suspected or confirmed hematological malignancies
- Have undergone 18F-FDG PET or other imaging as part of treatment plan
- For suspected cases, biopsy or needle biopsy expected to obtain pathology
- Able to provide informed consent and understand study requirements
You will not qualify if you...
- Pregnant or breastfeeding women
- Patients with fear of radiation, mental disorders, or primary affective disorders
- Received ionizing radiation exceeding 50 mSv in the past year from other medical or research sources
- Used investigational drugs or devices with uncertain safety or efficacy within last month
- Any condition deemed by study leaders to pose potential harm related to study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single day
Participants receive a single intravenous injection of 18F-Pentixafor followed by PET/CT or PET/MR imaging to assess hematological malignancies.
1 visit (in-person)
Duration - Up to 24 months
Participants are observed for up to 24 months to evaluate diagnostic efficacy and imaging performance over time.
Follow-up visits as per clinical care; visit schedule varies
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310003
Actively Recruiting
Research Team
P
Peipei Wang, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here